Table II.

EC₅₀ and efficacy of potential novel hPXR agonists identified from qHTS primary and follow-up studies

Chemical Name (CASRN, Supplier)	Structure	PXR
		Primary EC50 (μM) [Efficacy, (%)]	Follow-up EC50 (μM) [Efficacy, (%)]
1,3-Diphenylguanidine (102-06-7, Sigma)		8.0 ± 13.7 [461 ± 143]	2.7 ± 0.3 [393 ± 128]
AMI-193 (510-74-7, Tocris)		5.9 ± 0.6 [363 ± 57.7]	8.7 ± 1.1 [330 ± 40.1]
Bensulide (741-58-2, Sigma)		5.4 ± 0 [130 ± 20.3]	3.9 ± 0.2 [114 ± 9.87]
Bortezomib (179324-69-7, Selleck)		0.008 ± 0.0005 [97.7 ± 17.9]	0.02 ± 0.004 [83.8 ± 12.8]
Butachlor (23184-66-9, Sigma)		4.0 ± 4.0 [119 ± 49.2]	6.49 ± 2.9 [107 ± 26.0]
Carfilzomib (868540-17-4, Sequoia)		0.04 ± 0.024 [110 ± 10.3]	0.1 ± 0.02 [108 ± 23.9]
Clofarabine (123318-82-1, Sequoia)		0.7 ± 0.2 [112 ± 34.6]	3.3 ± 0.4 [214 ± 13.9]
Dasatinib (302962-49-8, Selleck)		0.3 ± 0.5 [84.6 ± 22.2]	0.6 ± 0.07 [127 ± 12.0]
Emetine (483-18-1, Enzo)		0.05 ± 0.04 [211 ± 74.0]	0.1 ± 0.01 [119 ± 8.89]
Etomidoline (21590-92-1, Pharmaron)		2.6 ± 1.3 [175 ± 74.6]	3.2 ± 0.4 [142 ± 19.4]
FR167356 (174185-16-1, Astellas Pharma)		3.0 ± 2.2 [178 ± 9.77]	7.1 ± 1.2 [145 ± 9.86]
Lacidipine (103890-78-4, Sequoia)		5.6 ± 5.5 [155 ± 70.5]	10.4 ± 4.4 [115 ± 15.0]
Liranaftate (88678-31-3, Sequoia)		5.5 ± 2.6 [148 ± 42.6]	4.5 ± 0.7 [144 ± 16.0]
Mosapride citrate (112885-42-4, Vitas)		8.8 ± 3.3 [222 ± 59.5]	10.8 ± 1.2 [138 ± 9.00]
Prodiamine (29091-21-2, Chemservice)		4.7 ± 0.8 [168 ± 31.0]	8.5 ± 0.9 [108 ± 6.61]
rac Benidipine hydrochloride (91599-74-5, Toronto Research)		5.6 ± 5.4 [141 ± 33.3]	4.6 ± 2.3 [105 ± 14.7]
Spiperone (749-02-0, Enzo)		3.7 ± 0.4 [341 ± 31.7]	6.2 ± 3.3 [345 ± 225]
Thiazopyr (117718-60-2, Chemservice)		1.2 ± 1.0 [108 ± 37.9]	4.6 ± 0.3 [102 ± 8.66]
Tolindate (27877-51-6, Pharmaron)		8.3 ± 2.3 [201 ± 37.5]	8.7 ± 1.5 [113 ± 7.13]
Vorinostat (SAHA) (149647-78-9, Prestwick Chemical, Inc.)		7.8 ± 3.8 [182 ± 46.9]	6.0 ± 1.9 [111 ± 28.5]
Zosuquidar trihydrochloride (167465-36-3, Selleck)		3.2 ± 1.7 [188 ± 41.7]	1.6 ± 0.3 [106 ± 9.09]